

Product datasheet for MR217206L3V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Kng1 (NM_001102411) Mouse Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: Kng1 (NM_001102411) Mouse Tagged ORF Clone Lentiviral Particle

Symbol: Kng1
Synonyms: Kng

Mammalian Cell Puromycin

Selection:

Vector:

pLenti-C-Myc-DDK-P2A-Puro (PS100092)

Tag: Myc-DDK

ACCN: NM_001102411

ORF Size: 1983 bp

ORF Nucleotide

The ORF insert of this clone is exactly the same as(MR217206).

OTI Disclaimer:

Sequence:

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeq: <u>NM 001102411.1</u>, <u>NP 001095881.1</u>

 RefSeq Size:
 2299 bp

 RefSeq ORF:
 1986 bp

 Locus ID:
 16644

 UniProt ID:
 008677

 Cytogenetics:
 16 B1







Gene Summary:

(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting (By similarity).[UniProtKB/Swiss-Prot Function]